Table 2.
Main characteristics of the studies included. Patients treated with EUS-guided EA technique. NA: not applicable, F: female, M:male, EA: etanol ablation, EUS: endoscopic ultrasound.
| Study population | Country | No. of patients with insulinoma | Gender (M\F) | Age (years) | Indication for EUS-EA | No of insulinomas | No of sessions | No of passes | Ethanol concentration (%) | Ethanol volume (ml) | Glucose (mmol/L) | Insulin (pmol/L) | C-peptid (pmol/L) | Type of adverse event | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| before EA | after EA | before EA | after EA | before EA | after EA | ||||||||||||
| Altonbary et al. 21 | Egypt | 1 | M | 35 | refuse surgery | 1 | 2 | 2 | NA | 6 | 1.67 | NA | 1632 | NA | NA | NA | no |
| Bor et al. 23 | Hungary | 1 | F | 83 | comorbidity | 1 | 1 | 2 | 96 | 3 | 1.7 | 3.5 | 185 | 25.7 | NA | NA | no |
| Burghardt et al. 6 | Germany | 1 | F | 65 | comorbidity | 1 | 1 | NA | 96 | 1 | 2.1 | 7.5 | 271 | NA | NA | NA | no |
| Dabkowski et al. 26 | Poland | 1 | F | 81 | comorbidity | 1 | 2 | NA | 96 | 3 | 1.61 | 4.61 | 231 | 34 | 1586 | 728 | no |
| Sousa et al. 27 | Portugal | 1 | F | 89 | comorbidity | 1 | 1 | NA | 95 | 0.6 | 2.11 | NA | 83.3 | NA | NA | NA | no |
| Deprez et al. 29 | Belgium | 1 | F | 78 | comorbidity | 1 | NA | NA | 98 | 3.5 | 1.9 | 6.2 | 229.6 | 43.1 | 1970 | NA | duodenal perforation |
| Jürgensen et al. 10 | Germany | 1 | F | 78 | refuse surgery | 1 | 1 | 4 | 95 | 8 | 0.8 | 5.3 | 560 | 41 | 3880 | 1560 | abd.pain |
| Lee et al. 35 | Korea | 1 | F | 26 | tumour location (multiple ins.) | 4 | 1 | 3 | 95 | 3.2 | 2 | 5.3 | 106.3 | 61.8 | 1200 | 600 | no |
| Levy et al. 36 | USA | 5 | F | 72 | comorbidity | 1 | 2 | 5 | 98 | 0.37 | NA | 7.77 | NA | NA | NA | NA | no |
| M | 82 | comorbidity | 1 | 3 | 7 | 95 | 0.62 | NA | |||||||||
| F | 80 | comorbidity | 1 | 2 | 9 | 98 | 1.23 | NA | |||||||||
| F | 57 | refuse surgery | 1 | 2 | 7 | 98 | 4.5 | NA | |||||||||
| M | 34 | refuse surgery | 1 | 2 | 9 | 99 | 1.7 | NA | |||||||||